How to buy INmune Bio stock

INmune Bio, Inc is a biotechnology business based in the US. INmune Bio shares (INMB) are listed on the NASDAQ and all prices are listed in US Dollars. INmune Bio employs 5 staff and has a trailing 12-month revenue of around 0.00.

INmune Bio share price

Use our graph to track the performance of INMB stocks over time.

INmune Bio shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$4.31 - $29.99
50-day moving average	$12.69
200-day moving average	$13.52
Wall St. target price	$29.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.62

Buy INmune Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy INmune Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of INmune Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

INmune Bio financials

Revenue TTM	$10,916
Gross profit TTM	$10,916
Return on assets TTM	-23.47%
Return on equity TTM	-38.8%
Profit margin	0%
Book value	$2.88
Market capitalisation	$174.9 million

TTM: trailing 12 months

Shorting INmune Bio shares

There are currently 573,977 INmune Bio shares held short by investors – that's known as INmune Bio's "short interest". This figure is 5.5% up from 544,246 last month.

There are a few different ways that this level of interest in shorting INmune Bio shares can be evaluated.

INmune Bio's "short interest ratio" (SIR)

INmune Bio's "short interest ratio" (SIR) is the quantity of INmune Bio shares currently shorted divided by the average quantity of INmune Bio shares traded daily (recently around 119578.54166667). INmune Bio's SIR currently stands at 4.8. In other words for every 100,000 INmune Bio shares traded daily on the market, roughly 4800 shares are currently held short.

However INmune Bio's short interest can also be evaluated against the total number of INmune Bio shares, or, against the total number of tradable INmune Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case INmune Bio's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 INmune Bio shares in existence, roughly 40 shares are currently held short) or 0.0645% of the tradable shares (for every 100,000 tradable INmune Bio shares, roughly 65 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against INmune Bio.

Find out more about how you can short INmune Bio stock.

INmune Bio share dividends

We're not expecting INmune Bio to pay a dividend over the next 12 months.

INmune Bio share price volatility

Over the last 12 months, INmune Bio's shares have ranged in value from as little as $4.3101 up to $29.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while INmune Bio's is 2.8077. This would suggest that INmune Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.

INmune Bio overview

INmune Bio, Inc. , a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc. ; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc.

Frequently asked questions

• What percentage of INmune Bio is owned by insiders or institutions?

  Currently 40.587% of INmune Bio shares are held by insiders and 10.531% by institutions.

• How many people work for INmune Bio?

  Latest data suggests 5 work at INmune Bio.

• When does the fiscal year end for INmune Bio?

  INmune Bio's fiscal year ends in December.

• Where is INmune Bio based?

  INmune Bio's address is: 1200 Prospect Street, La Jolla, CA, United States, 92037

• What is INmune Bio's ISIN number?

  INmune Bio's international securities identification number is: US45782T1051

• What is INmune Bio's CUSIP number?

  INmune Bio's Committee on Uniform Securities Identification Procedures number is: 45782T105